Onderneming Nanoform Finland Oyj Nasdaq Helsinki
Aandelen
FI4000330972
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Nanotechnology and Drug Particle Engineering
100,0
%
| 3 | 100,0 % | 3 | 100,0 % | -26,41% |
Verkoop per regio
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Europe
57,0
%
| 2 | 56,2 % | 1 | 57,0 % | -25,37% |
United States
43,0
%
| 2 | 43,8 % | 1 | 43,0 % | -27,73% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Edward Hæggström
CEO | Chief Executive Officer | 55 | 01-01-15 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 01-01-15 |
Investor Relations Contact | - | 01-05-19 | |
Antonio da Silva
PRN | Corporate Officer/Principal | 50 | 01-01-19 |
Peter Hänninen
LAW | General Counsel | 36 | 01-09-20 |
David Rowe
PRN | Corporate Officer/Principal | 57 | 01-01-19 |
Christian Jones
PRN | Corporate Officer/Principal | 44 | 01-01-18 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 68 | 02-04-19 | |
Mads Laustsen
BRD | Director/Board Member | 67 | 01-01-19 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 01-01-15 |
Jeanne A. Thoma
BRD | Director/Board Member | 64 | 01-10-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 85 445 164 | 59 636 291 ( 69,79 %) | 0 | 69,79 % |
Bedrijfsgegevens
Sector
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
+44,48% | 54,04 mld. | |
+43,57% | 41,96 mld. | |
-0,86% | 41,92 mld. | |
-7,59% | 28,35 mld. | |
+12,30% | 26,35 mld. | |
-21,83% | 19 mld. | |
+7,15% | 13 mld. | |
+29,40% | 12,28 mld. | |
+25,15% | 12,19 mld. |